GSK ADR had its Relative Strength (RS) Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary rating measures price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves. See if GSK ADR can continue to show renewed price strength and hit that benchmark.
GSK ADR is building a consolidation with a 45.92 entry. See if the stock can break out in heavy trade.
The company reported negative growth for both sales and earnings last quarter. The company is expected to release its next quarterly numbers on or around Apr. 30.
The company earns the No. 5 rank among its peers in the Medical-Diversified industry group. Eli Lilly is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
